United States · FDA National Drug Code directory
ADSTILADRIN
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 55566-1050_dac17f96-6c26-41e4-bd42-92aff75d339e
- Product NDC
- 55566-1050
- Form
- SUSPENSION
- Composition / generic term
- nadofaragene firadenovec-vncg
- Labeler
- Ferring Pharmaceuticals Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20230905
- Source listing expiry
- 20271231
Source-listed ingredients
- NADOFARAGENE FIRADENOVEC — 300000000000 {VP}/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 4 VIAL in 1 CARTON (55566-1050-1) / 20 mL in 1 VIAL (55566-1050-0) · 55566-1050-1
- 20 mL in 1 VIAL (55566-1050-2) · 55566-1050-2
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →